| Symbol | PYPD |
|---|---|
| Name | POLYPID LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 18 HASIVIM STREET, PETACH TIKVA, 495376, Israel |
| Telephone | +972 747195700 |
| Fax | — |
| — | |
| Website | https://www.polypid.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001611842 |
| Description | PolyPid Ltd is a clinical stage specialty pharmaceutical company engaged in research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the Companys proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, BonyPid-1000, BonyPid-500, PLEX, and D-PLEX are trademarks of the Company. The Company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies. Additional info from NASDAQ: |
New Form S-8 - PolyPid Ltd. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001213900-26-088332 <b>Size:</b> 249 KB
Read moreNew Form SCHEDULE 13G/A - PolyPid Ltd. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001622627-26-000017 <b>Size:</b> 15 KB
Read morePolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Read morePolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
Read morePolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
Read morePolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
Read moreWarshavsky Ori 🟢 acquired 46.0K shares (1 derivative) of PolyPid Ltd. (PYPD) at $4.46 Transaction Date: May 11, 2026 | Filing ID: 079167
Read moreMissulawin Jonathan 🟢 acquired 49.0K shares (1 derivative) of PolyPid Ltd. (PYPD) at $4.46 Transaction Date: May 11, 2026 | Filing ID: 079162
Read moreHazan Dalit Fellous 🟢 acquired 75.0K shares (1 derivative) of PolyPid Ltd. (PYPD) at $4.46 Transaction Date: May 11, 2026 | Filing ID: 079161
Read moreDirector Barenholz Yechezkel 🟢 acquired 9.1K shares (1 derivative) of PolyPid Ltd. (PYPD) at $4.46 Transaction Date: Jul 15, 2026 | Filing ID: 079159
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04411199 | D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal … | Phase3 | Surgical Site Infection | Completed | 2020-12-15 | 2025-05-10 | ClinicalTrials.gov |
| NCT04233424 | D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal S… | Phase3 | Surgical Site Infection | Completed | 2020-06-24 | 2022-09-02 | ClinicalTrials.gov |
| NCT03558984 | D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infectio… | Phase3 | Surgical Site Infection | Terminated | 2019-12-17 | 2022-10-24 | ClinicalTrials.gov |
| NCT03633123 | D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal S… | Phase2 | Abdominal Surgery | Completed | 2018-10-04 | 2019-10-06 | ClinicalTrials.gov |
| NCT02731573 | Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardi… | Phase1 | Postoperative Wound Infection Superficial Incisional | Completed | 2016-10-12 | 2018-05-01 | ClinicalTrials.gov |
| NCT02531100 | BonyPid-500TM Bone Graft Substitute Study | Na | Peri Implantitis | Completed | 2016-03-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT02491047 | Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo I, II, IIIA… | Na | Tibial Fractures | Completed | 2015-10-01 | 2018-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Standard of Care | Other | Phase PHASE3 | Surgical Site Infection | TERMINATED | NCT03558984 |
| D-PLEX | Other | Phase PHASE3 | Surgical Site Infection | TERMINATED | NCT03558984 |
| SOC treatment only | Drug | Approved | Peri Implantitis | COMPLETED | NCT02531100 |
| BonyPid 500TM implantation concomitantly to SOC treatment | Drug | Approved | Peri Implantitis | COMPLETED | NCT02531100 |
| Standard of Care (SOC) treatment | Drug | Approved | Tibial Fractures | COMPLETED | NCT02491047 |
| BonyPid-1000 | Other | Approved | Tibial Fractures | COMPLETED | NCT02491047 |
| Standard of Care | Other | Phase PHASE3 | Surgical Site Infection | TERMINATED | NCT03558984 |
| D-PLEX | Other | Phase PHASE3 | Surgical Site Infection | TERMINATED | NCT03558984 |
| Standard of Care (SoC) | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04411199 |
| D-PLEX | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04411199 |
| Open heart surgery | Procedure | Phase PHASE1 | Postoperative Wound Infection Superficial Incisional | COMPLETED | NCT02731573 |
| D-PLEX | Other | Phase PHASE1 | Postoperative Wound Infection Superficial Incisional | COMPLETED | NCT02731573 |
| Standard of Care (SoC) | Other | Phase PHASE2 | Abdominal Surgery | COMPLETED | NCT03633123 |
| D-PLEX | Other | Phase PHASE2 | Abdominal Surgery | COMPLETED | NCT03633123 |
| Standard of Care (SoC) | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| D-PLEX | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| Standard of Care (SoC) | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| D-PLEX | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| Standard of Care (SoC) | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| D-PLEX | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| Standard of Care (SoC) | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| D-PLEX | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| Standard of Care (SoC) | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| D-PLEX | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| Standard of Care (SoC) | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| D-PLEX | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| Standard of Care (SoC) | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| D-PLEX | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| Standard of Care (SoC) | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| D-PLEX | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| Standard of Care (SoC) | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| D-PLEX | Other | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04233424 |
| Standard of Care (SoC) | OTHER | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04411199 |
| Standard of Care | OTHER | Phase PHASE3 | Surgical Site Infection | TERMINATED | NCT03558984 |
| Open heart surgery | PROCEDURE | Phase PHASE1 | Postoperative Wound Infection Superficial Incisional | COMPLETED | NCT02731573 |
| D-PLEX | DRUG | Phase PHASE3 | Surgical Site Infection | COMPLETED | NCT04411199 |
| SOC treatment only | OTHER | Approved | Peri Implantitis | COMPLETED | NCT02531100 |
| BonyPid 500TM implantation concomitantly to SOC treatment | DEVICE | Approved | Peri Implantitis | COMPLETED | NCT02531100 |
| Standard of Care (SOC) treatment | OTHER | Approved | Tibial Fractures | COMPLETED | NCT02491047 |
| BonyPid-1000 | DEVICE | Approved | Tibial Fractures | COMPLETED | NCT02491047 |